問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Cardiovascular Diseases

Division of Cardiovascular Diseases

Kaohsiung Municipal Ta-Tung Hospital (在職)

更新時間：2023-09-19

盧怡旭Lu, Ye-Hsu
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

42Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

盧怡旭

List

85Cases

2014-06-01 - 2016-08-31

Phase III

A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

  • Condition/Disease

    Treatment of Type 2 Diabetes Mellitus (T2DM)

  • Test Drug

    Ertugliflozin

Participate Sites
5Sites

Terminated5Sites

2007-07-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2007-07-01 - 2009-03-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2013-11-01 - 2014-11-30

Phase III

A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension who are Inadequately Controlled on Nifedipine Gastrointestinal Therapeutic System Monotherapy

  • Condition/Disease

    Treatment of essential hypertension inadequately controlled by monotherapy

  • Test Drug

    BAY 98-7106( Nifedipine GITS / Candesartan cilexetil fixed dose combination)

Participate Sites
5Sites

Terminated5Sites

2022-06-01 - 2024-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2007-09-01 - 2008-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2010-10-01 - 2016-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-04-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Study ended7Sites

2013-01-10 - 2015-12-31

Phase III

A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C

  • Condition/Disease

    Hyperlipidemia

  • Test Drug

    MK859/Placebo

Participate Sites
9Sites

Terminated9Sites

2010-08-30 - 2012-11-30

Phase III

A Phase III, Prospective, Randomized, Double-Blind, PlaceboControlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients with Atrial Fibrillation

  • Condition/Disease

    Atrial Fibrillation

  • Test Drug

    MK-6621

Participate Sites
16Sites

Terminated16Sites

1 4 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB